DaVita Receives a Hold from RBC Capital

By Austin Angelo

RBC Capital analyst Frank Morgan reiterated a Hold rating on DaVita (NYSE: DVA) today and set a price target of $62. The company’s shares opened today at $65.50.

According to TipRanks.com, Morgan is a 5-star analyst with an average return of 10.8% and a 66.7% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care Corp, Quest Diagnostics Inc, and Surgery Partners Inc.

DaVita has an analyst consensus of Hold, with a price target consensus of $64.75.

Based on DaVita’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.73 billion and quarterly net profit of $571 million. In comparison, last year the company earned revenue of $3.53 billion and had a GAAP net loss of $6 million.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2016, Kent Thiry, the Chairman & CEO of DVA sold 32,880 shares for a total of $2,531,431.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DaVita, Inc. engages in the provision of medical care services. It operates through Kidney Care and HealthCare Partners segments. The Kidney Care segment focuses on the delivery of dialysis services to patients with chronic kidney failure and end stage renal disease. The HealthCare Partners segment deals with the management and operation of medical groups and affiliated physician networks in California, Nevada, New Mexico, Florida, Colorado, and Washington. The company was founded in 1994 and is headquartered in Denver, CO.